Coherus Oncology (CHRS) 2026 Global Healthcare Conference summary

Strategic focus and immune resistance

• Strategy centers on overcoming tumor immune resistance; chemotherapy, radiation, VEGF-targeted therapies, KRAS therapies and ADCs can increase suppressive Tregs in the tumor microenvironment.

• Tagmokitug targets CCR8+ Tregs for selective depletion; the Tumor Immune Regulatory Index (TIRI) is intended to help identify tumors more likely to respond.

• LOQTORZI is positioned both as a nasopharyngeal cancer revenue driver and as a potential combination product alongside pipeline assets.

Tagmokitug

• CCR8-targeting antibody screened against over 5,500 cell-surface proteins with no off-target binding reported; properties include picomolar affinity and enhanced ADCC and ADCP activity.

• Phase I head and neck data showed reduced intratumoral CCR8+ Tregs and increased CD8+ T-cell infiltration; a fourth-line patient responded to tagmokitug plus toripalimab after prior PD-1, taxane and TKI treatment.

• Second-line head and neck study enrolled 40 patients at two doses with toripalimab; full data readout expected in October 2026. Management cited manageable safety, activity and greater activity in HPV-positive and high-TIRI subgroups.

• GI program includes second-line upper GI adenocarcinoma and esophageal squamous cell cohorts, first-line esophageal squamous cell combination with chemotherapy, and fourth-line-plus MSS colorectal cancer.

• Fourth-line-plus MSS colorectal cohort initially targets patients without liver metastases; initial 20-patient accrual was complete. Prostate cancer combination with J&J's pasritamig is on track to start in fall 2026, with data expected in H1 2027.

Casdozokitug

• First-in-class IL-27 antagonist is being studied in first-line HCC; IL-27 can suppress T-cell and natural-killer-cell activity and reduce pro-inflammatory cytokines.

• Completed study adding casdozokitug to atezolizumab and bevacizumab reported ORR 38%, CR rate 17% and PFS 8.1 months; activity occurred in viral and non-viral disease. Comparisons with IMbrave150 were cross-trial.

• Ongoing randomized, three-arm study enrolled 72 patients and completed accrual: two casdozokitug doses with toripalimab/bevacizumab, plus a toripalimab/bevacizumab control arm. Data expected toward year-end 2026.

• Trial includes ctDNA and IL-27 biomarker assessments; management expects the potential benefit to be primarily in response durability.